Otsuka Pharmaceutical Company, Limited

Kuninori Tai

Hirofumi Sasaki

Nobuaki Ito

Tomoichi Shinohara

Yasuhiro Menjo

Shinichi Taira

Noriaki Takemura

Shin Miyamura

Yohji Sakurai

Takayuki Matsuzaki

Muneaki Kurimura

Takahiro Tomoyasu

Yasuyo Sakata

Takumi Masumoto

Kohei Akazawa

Haruhiko Sugino

Naoki Amada

Satoshi Ohashi

Junko Yamashita

Akihito Watanabe

Chisako Morita

Satoko Nakajima

Motohiro Itotani

Hokuto Yamabe

Masataka Ueda

Shuuji Matsumura

Takashi Oshiyama

Makoto Matsumoto

Hidetsugu Tsubouchi

Kunio Oshima

Takumi Sumida

Yasuo Koga

Tae Fukushima

Yoshikazu Haraguchi

Satoshi Matsuda

Hiroyuki Hashizume

Toshiyuki Onogawa

Kenji Tsujimae

Sunao Nakayama

Hiroshi Shimizu

Michiaki Tominaga

Satoshi Yamada

Takashi Suzuki

Takashi Nakagawa

Seiji Sato

Takao Nishi

Takeshi Kuroda

Hideaki Kuroda

Hitoshi Tone

Makoto Sakamoto

Koichi Yasumura

Michinori Tanaka

Seiji Akamatsu

Takashi Okamoto

Shigekazu Fujita

Isao Takemura

Keizo Kan

Yasuo Yanagihara

Yutaka Kojima

Keisuke Miyajima

Makoto Komatsu

Masanori Kawasaki

Takeshi Hasegawa

Kazuhisa Sugiyama

Hideki Takasu

Naoto Ohi

Mitsuhiro Okuno

Takeshi Kodama

Kunihiko Kiyono

Takuya Shitsuta

Yoshikazu Kawano

Kenji Watanabe

Hitoshi Nagao

Yukitaka Uematsu

Toshio Shinohara

Tatsuo Tomishige

Hironori Tsutsui

Miki Matsuba

Naohide Kanemoto

Shuji Matsumura

Hideaki Satou

Yuji Seike

Jun-ichi Minamikawa

Akihiro Hashimoto

Hiromi Yata

Kazuho Kohashi

Mikayo Hayashi

Izuru Nakamura

Xiuhao Chen

Naohiro Isono

Chiharu Matsumura

Tsuyoshi Nagase

Harukiho Sugino

A heterocyclic compound represented by the general formula (1) or a salt thereof: 

Methods of treating anxiety by administering a substituted quinolone

This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

Cyanotriazole compounds

Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine

Method for treating depression and/or depression status with substituted quinoxaline compounds

The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein Rand Rare each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents &#x2014;O&#x2014; or &#x2014;CH&#x2014;;Rrepresents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group;Rand R, which are the same or different, each independently represent hydrogen or a lower alkyl group; or Rand Rare bonded to form a cyclo-C3-C8 alkyl group; andRrepresents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

Substituted quinoxalines compounds

The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof,

6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides

The present invention provides a novel diazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The present invention relates to a diazepine compound represented by General Formula (1)  

Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1) wherein R, R, R, and Rare each independently hydrogen or lower alkyl; Rand Rmay be linked to form lower alkylene; wherein Rand Rare each independently hydrogen or organic group;

Benzodiazepine compound and pharmaceutical composition

N, N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1)  

The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein Xrepresents a nitrogen atom or a group &#x2014;CH&#x2550;; Rrepresents a group &#x2014;Z&#x2014;R, wherein Z represents a group &#x2014;CO&#x2014;, a group &#x2014;CH(OH)&#x2014;, or the like, and Rrepresents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; Rrepresents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group &#x2014;O&#x2014;, a group &#x2014;CO&#x2014;, a group &#x2014;CH(OH)&#x2014;, a lower alkylene group, or the like; and A represents a group or the like, wherein Rrepresents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and Rrepresents an imidazolyl lower alkyl group or the like.

Aromatic compounds for suppressing the generation of collagen

Growing community of inventors

Osaka, Japan

Kuninori Tai